{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:39:36Z","timestamp":1649007576458},"reference-count":18,"publisher":"Hogrefe Publishing Group","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p> Zusammenfassung. Wir stellen den Fall einer 83-j\u00e4hrigen Patientin vor, die in der Folge verschiedener, wahrscheinlich medikamenteninduzierter Komplikationen (Agranulozytose unter Metamizol und Cefepim-induzierte Enzephalopathie) gestorben ist. Bei ersten Symptomen (z.B. Fieber, Mukositis, Halsschmerzen) ist Metamizol sofort zu stoppen und eine Reexpositionen durch nachhaltige Dokumentation und Ausgabe eines Notfall- oder Allergiepasses zu vermeiden. Bei Anwendung von Cefepim ist die Nierenfunktion gerade beim multimorbiden geriatrischen Patienten engmaschig zu \u00fcberwachen und die Dosis entsprechend anzupassen. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003275","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:00:22Z","timestamp":1565157622000},"page":"693-697","source":"Crossref","is-referenced-by-count":1,"title":["Agranulozytose nach Metamizol-Reexposition und Cefepim-induzierte                     Enzephalopathie mit fatalem Ausgang"],"prefix":"10.1024","volume":"108","author":[{"given":"Ana","family":"Skaistys","sequence":"first","affiliation":[{"name":"Universit\u00e4re Altersmedizin FELIX PLATTER, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra E.","family":"R\u00e4tz Bravo","sequence":"additional","affiliation":[{"name":"Universit\u00e4re Altersmedizin FELIX PLATTER, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Leuppi-Taegtmeyer","sequence":"additional","affiliation":[{"name":"Klinische Pharmakologie & Toxikologie, Universit\u00e4tsspital Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Zysset","sequence":"additional","affiliation":[{"name":"Universit\u00e4re Altersmedizin FELIX PLATTER, Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01595-08"},{"key":"c2","unstructured":"The use of the WHO-UMC                         system for standardised case causality assessment [Internet]. [cited Octobre 28, 2018].                         http:\/\/www. who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHO                         causality_assessment.pdf; letzer Zugriff:                         24.10.2018."},{"key":"c3","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1781-z"},{"key":"c4","doi-asserted-by":"publisher","DOI":"10.4414\/smf.2017.03098"},{"key":"c5","doi-asserted-by":"publisher","DOI":"10.1007\/s00482-016-0160-3"},{"key":"c6","first-page":"w14438","volume":"147","author":"Blaser L","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"c7","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120037425"},{"key":"c8","unstructured":"Drug-induced neutropenia and                         agranulocytosis. https:\/\/www.uptodate.com\/contents\/drug-induced-neutropenia-and-agranulocytosis;                         letzter Zugriff: 24.04.2018."},{"key":"c9","unstructured":"Novalgin\u00ae.                         Arzneimittelkompendium der Schweiz Fachinformation Novalgin.                         2018. https:\/\/compendium.ch\/mpro\/mnr\/1736\/html\/de; letzter                         Zugriff: 02.05.2019."},{"key":"c10","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1618-1"},{"key":"c11","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1777-8"},{"key":"c12","doi-asserted-by":"publisher","DOI":"10.1024\/1661-8157\/a001916"},{"key":"c13","unstructured":"FDA Drug Safety                         Communication: Cefepime and risk of seizure in                         patients not receiving dosage adjustments for kidney                         impairment 2012. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm309661.htm;                         letzer Zugriff: 05.06.2018."},{"key":"c14","unstructured":"Cefepim Sandoz\u00ae.                         Arzneimittelkompendium der Schweiz. 2018.                         https:\/\/compendium.ch\/mpro\/mnr\/20891\/html\/de; letzter                         Zugriff: 02.05.2019."},{"key":"c15","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1856-1"},{"key":"c16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00767-7"},{"key":"c17","doi-asserted-by":"publisher","DOI":"10.1016\/S0987-7053(00)00234-3"},{"key":"c18","first-page":"199","volume":"6","author":"Lindsay H","year":"2017","journal-title":"J Pediatr Infect Dis"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T01:28:58Z","timestamp":1615944538000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1024\/1661-8157\/a003275"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003275","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}